Ultrasound showdown: which test best spots returning liver cancer?

NCT ID NCT07600346

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two contrast-enhanced ultrasound scoring systems (LI-RADS and ESCULAP) to see which one better detects recurrent liver cancer in 105 patients who have had surgery for hepatocellular carcinoma. The goal is to improve diagnostic accuracy for new liver lesions. Participants will receive a contrast-enhanced ultrasound, and results will be checked against biopsy or follow-up data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Contrast-enhanced ultrasound (with injected contrast agent)

What this could lead to

If this study succeeds, it could help doctors more accurately detect returning liver cancer after surgery, potentially leading to earlier treatment.

What could go wrong

This is an early-stage diagnostic comparison study, not a treatment trial. The results may not change current practice, and the methods may not work equally well for all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRAST-ENHANCED ULTRASOUND are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.